Compare Nebius Group NV (NBIS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Twist Bioscience Corp — how do they compare? Nebius Group NV trades at $215.29 (market cap $46.37B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Nebius Group NV is far larger — about 8.5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| NBIS | TWST | |
|---|---|---|
Market Cap | $46.37B | $5.45B |
Sector | Technology | Health |
52-Week High | $286.69 | $102.88 |
52-Week Low | $50.40 | $24.16 |
Enterprise Value | $46.56B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $182.62, up 2.76% today, with a bearish technical signal despite oversold RSI readings. The company reported a net income of $82.50M in 2025, with revenue of $529.80M, and shows strong projected profit margin expansion to 93.08% in 2026. Recent news highlights a significant stake increase by Nvidia, fueling positive sentiment.
Outlook is mixed: strong analyst support (88.89% buy ratings) and a $260.67 price target suggest upside, but high valuation ratios (P/E 70.51) and negative cash flow from investing pose risks. Investor focus is on execution of AI-driven growth amid competitive pressures.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
